Close
Enter your
text here

minority diseases

A music therapy study for children and adolescents with Fragile X syndrome wins the Pau Massana Grant
 A music therapy study for children and adolescents with Fragile X syndrome wins the Pau Massana Grant 1080 608 Oriol Capell
By:
The project will analyze how music can influence the physical, mental and emotional well-being of people suffering from this rare disease. read more
Parc Taulí will evaluate a new therapy for Angelman syndrome
 Parc Taulí will evaluate a new therapy for Angelman syndrome 1080 608 Oriol Capell
By:
The center is participating in an international clinical trial that seeks to improve patients' quality of life by addressing sleep, communication and motor disorders. read more
A project for research into Prader-Willi syndrome, winner of the Pau Massana Grant
 A project for research into Prader-Willi syndrome, winner of the Pau Massana Grant 1080 608 Oriol Capell
By:
For three editions, the I3PT has collaborated with Cellers Maset for the research and development of projects that improve the quality of life of people with rare diseases. read more
A project for the research of Angelman syndrome, winner of the Pau Massana Grant
 A project for the research of Angelman syndrome, winner of the Pau Massana Grant 1080 608 Oriol Capell
By:
The study, led by researchers Marta Moraleda and Débora Itzep, will investigate the sleep and circadian rhythm disorders of children and adolescents with this pathology read more
Investigating Fragile X syndrome in girls and adolescents
 Investigating Fragile X syndrome in girls and adolescents 1080 608 Oriol Capell
By:
As part of World Minority Disease Day, we are publishing the second installment of the 'Presenta la teva tesi' series. Lorena Joga, child and youth neuropsychologist at Parc Taulí and researcher at the I3PT explains what Fragile X Syndrome is and how it affects girls and teenagers. read more
I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome
 I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome 1080 608 Mireia Córcoles
By:
The Phase IIa study will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with FXS, the most common form of inherited intellectual disability without a specific treatment read more
  • 1
  • 2
Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.